PAXMAN's major shareholders are reducing their shareholdings

PAXMAN announces today that the company’s founder and board member Glenn Paxman, CIMON Venture Trust AB (represented by the chairman Per-Anders Johansson) and the board members Björn Littorin and Robert Kelly have sold shares in the company. All selling parties have entered a lock-up agreement for 180 days.
In total, the transaction amounts to 2 000,000 shares.

Among the new owners are SEB Investment Management, Carnegie Fonder, Aktia Asset Management and Adrigo Asset Management.

The CEO Richard Paxman comments: ”I am delighted to welcome our new shareholders to Paxman. The high level of interest in the company is a clear signaller of our performance but more importantly our future opportunity to build a strong profitable business providing a clear impact socially. I am also pleased for our long standing shareholders including our founder to enjoy a return on their investment whilst enhancing our shareholder base. I look forward to 2025 and beyond with our new and existing investors.”

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 5,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK), Houston, Texas (US) and Toronto, Ontario (CA).

The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company’s Certified Adviser.

PAXMAN's major shareholders are reducing their shareholdings

PAXMAN's major shareholders are reducing their shareholdings PAXMAN's major shareholders are reducing their shareholdings

What we do

Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.

Learn more →

Financial Information

Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.

Read reports →

Investing in Paxman

Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.

Visit the Investor Centre →

Stay in the loop

Contact

Paxman Coolers Limited
International House, Penistone Road
Fenay Bridge, Huddersfield
West Yorkshire, UK
HD8 0LE

Paxman AB (publ)
Pirgatan 13
SE-374 35 KARLSHAMN
Sweden

IR Contact

IR Contact
Emelie Gustafsson, CFO
Tel +46 (0)70 – 454 37 91
Email: emelie.gustafsson@paxman.se